---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023094"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2026-05-14T20:15:44+00:00"
generated_at: "2026-05-14T20:51:11.246622+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track

## Summary
- Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.
- Cash and restricted cash $6.8M as of Mar 31, 2026; up from $5.8M at Dec 31, 2025.
- G&A expenses fell $1.0M to $1.6M; R&D expenses rose to $2.6M from $2.4M.
- CLD-401 IND submission expected by end of 2026; AACR data showed T, NK, and γδ T-cell activation.
- Entered partnership with TransferAI to use AI platform to streamline CLD-401 IND submission.

## SEC filing metadata
- accession: 0001493152-26-023094
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2026-05-14T20:15:44+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/0001493152-26-023094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023094
- JSON: https://secwatch.observer/filing/0001493152-26-023094.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023094.txt

## Key facts
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income net loss attributable to common stockholders of $4.4 million, or $0.43 per share, EPS $0.43 per share.
  - Period: the first quarter ended March 31, 2026
  - Net income: net loss attributable to common stockholders of $4.4 million, or $0.43 per share
  - EPS: $0.43 per share
  - Result: reported results
  source text: The Company reported a net loss attributable to common stockholders of $4.4 million, or $0.43 per share, for the three months ended March 31, 2026, compared to a net loss attributable to common stockholders of $5.0 million, or $2.21 per share, for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/0001493152-26-023094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.